![]() | License: Creative Commons Attribution Non-commercial 4.0 PDF - Published Version (475kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-585588
- DOI to cite this document:
- 10.5283/epub.58558
Abstract
Heart failure with preserved ejection fraction (HFpEF) constitutes approximately half of all patients with heart failure and causes mortality similar to heart failure with reduced ejection fraction [1]. HFpEF is highly relevant as novel evidence-based therapies emerge but treatment options remain limited [1]. Diastolic dysfunction is a hallmark of HFpEF and is also very common in up to 80% of ...

Owner only: item control page